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ABSTRACT
Androgen receptor (AR)-mediated pathways play a
critical role in the development and progression of
prostate cancer. However, little is known about the
regulation of AR mRNA stability and translation, two
central processes that control AR expression. The
ErbB3 binding protein 1 (EBP1), an AR corepressor,
negatively regulates crosstalk between ErbB3
ligand heregulin (HRG)-triggered signaling and the
AR axis, affecting biological properties of prostate
cancer cells. EBP1 protein expression is also
decreased in clinical prostate cancer. We previously
demonstrated that EBP1 overexpression results
in decreased AR protein levels by affecting AR
promoter activity. However, EBP1 has recently
been demonstrated to be an RNA binding protein.
We therefore examined the ability of EBP1 to
regulate AR post-transcriptionally. Here we show
that EBP1 promoted AR mRNA decay through
physical interaction with a conserved UC-rich
motif within the 30-UTR of AR. The ability of EBP1
to accelerate AR mRNA decay was further enhanced
by HRG treatment. EBP1 also bound to a
CAG-formed stem-loop in the 50 coding region of
AR mRNA and was able to inhibit AR translation.
Thus, decreases of EBP1 in prostate cancer
could be important for the post-transcriptional
up-regulation of AR contributing to aberrant AR
expression and disease progression.
INTRODUCTION
Prostate cancer remains a commonly diagnosed invasive
cancer in men in the USA and other industrial countries.
Androgen receptor (AR), a member of the nuclear
receptor superfamily of transcription factors, is a critical
molecule in the etiology of both early and advanced stages
of the disease (1–3). A correlation between AR levels and
disease progression has been reported in both humans and
animal models (4). Strategies targeting AR in vitro and in
animal models (5–8) have been shown to ameliorate
hormone refractory disease. However, insights into AR
mRNA stability and translation, central to the regulation
of AR expression, are still largely lacking.
EBP1, an ErbB3 binding protein, was identiﬁed as an
AR corepressor (9). A role for EBP1 in the progression of
prostate cancer was suggested by studies indicating that
EBP1 expression is signiﬁcantly reduced in preclinical
models of hormone-refractory prostate cancer (7) and in
advanced stages of clinical prostate cancer (8). Ectopic
expression of EBP1 inhibited prostate cancer cell growth
both in vitro and in xenograft mouse models of prostate
cancer (9), decreased expression of androgen-regulated
genes such as PSA, and altered the cellular response to
HRG and androgens (7). Conversely, ablation of EBP1
expression resulted in increased cell growth in the
absence of androgen, increased PSA production and
activated AKT signaling (8).
These changes in biological responsiveness were
postulated to be due in part to changes in levels of AR.
For example, forced expression of exogenous EBP1
cDNA in hormone responsive LNCaP cells led to
decreases of several AR-target genes including AR itself
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mice expressed higher levels of AR protein in prostate tis-
sue as compared to age-matched controls (10). EBP1 was
demonstrated to bind to androgen response elements in
AR-regulated promoters (11,12), leading to decreases
in AR mRNA transcription. The ability of EBP1 to
decrease AR transcription was mediated in part by its
interactions with Sin3A and HDAC2. Although AR
mRNA transcription was decreased, AR protein levels
were down-regulated to a greater extent than mRNA
levels (7). This is an important observation, as EBP1, a
highly conserved and ubiquitously expressed protein, also
interacts with other proteins (13,14), and RNA (15–18),
suggesting a versatile role in the transcription and
post-transcriptional regulation of an array of genes.
These observations are supported by the crystal structure
of EBP1 (19,20), which demonstrates the ability of EBP1
to bind DNA, RNA and protein. We thus hypothesized
that EBP1 regulation of mRNA stability and translation is
an important determinant of AR gene expression (21).
Our current work indentiﬁed EBP1 as a novel AR
mRNA-binding protein and suggests that targeting
EBP1 has potential mechanistic and functional signiﬁ-
cance in the therapeutic management of prostate cancer.
MATERIALS AND METHODS
Cell culture and reagents
The generation of LNCaP cells stably transfected with
EBP1 cDNA, mutant (
354LXXLL
358 to
354LKAAA
358)
EBP1 cDNA or a control vector and LNCaP EBP1-
silenced C13 and control A16 cells, was previously
described (8,9). 22Rv1 cells (a gift from Dr Yun Qiu,
University of Maryland) stably transfected with CMV10-
EBP1 cDNA or a control vector, were established as
previously described (22). HRG and EGF were purchased
from R&D Systems (Mpls, MN, USA) and Cell Signaling
(Danvers, MA, USA), respectively.
Analysis of mRNA stability by Actinomycin D
chase assays
Cells were serum-starved overnight, then incubated with
or without heregulin (20ng/ml) for 12h followed by
addition of Actinomycin D (Act D) (5mg/ml). Cells were
harvested at subsequent time intervals (0, 2, 4, 6 and 8h).
Total RNA was extracted with Trizol and DNAse-treated
for quantitative real-time PCR (RT-qPCR) analysis. To
monitor reporter pGL3-ARUC and control pGL3-Luc
(PGL3-con) mRNA decay, A16 and C13 cells were
transfected with pGL3-ARUC and control pGL3-luc
vector. Forty-eight hours later, cells were treated with
Act D (5mg/ml) and RNA was extracted at 0, 2, 4, 6
and 8h, followed by RT-qPCR for luc mRNA. Data
from Act D assays were processed using the Prism 3.03
software to calculate the time required for each mRNA to
reach one-half of its initial abundance and P-value. Error
bars represent the SD of three independent experiments.
Ribonucleoprotein immunoprecipitation assays
For immunoprecipitation (IP) of endogenous AR mRNA-
EBP1 protein complexes [ribonucleoprotein (RNP)], cell
lysates (1.5mg) were incubated for 2h at 4 C with protein
A-sepharose beads (Calbiochem) that had been precoated
with 3mg of either rabbit IgG (BD Biosciences, San Jose,
CA, USA), mouse IgG (Sigma, St Louis, MO, USA) or
antibodies recognizing EBP1 (Upstate, Lake Placid, NY,
USA) or HuR, a ubiquitous RNA-binding protein (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Beads were
washed with NT2 buﬀer [50mM Tris–HCl (pH 7.4),
150mM NaCl, 1mM MgCl2 and 0.05% Nonidet P-40],
incubated with 20U of RNase-free DNase I (15min,
30 C), followed by incubation with 100ml NT2 buﬀer con-
taining 0.1% SDS and 0.5mg/ml proteinase K for another
30min at 55 C. The RNA isolated from the IP was con-
verted to cDNA using gene-speciﬁc primer pairs and
ampliﬁed by RT-qPCR as described (11).
Linear sucrose gradient fractionation
Linear sucrose gradient fractionation was performed as
described previously (23) with minor modiﬁcations. A
total of 50-million cells were incubated with cyclo-
heximide (100mg/ml) for 15min to arrest polyribosome
migration. Then 0.5ml of each cell lysate was loaded
onto sucrose gradients [10–50 w/v, 100mM KCl, 20mM
Tris–HCl (pH 7.5) and 5mM MgCl2]. After centrifugation
(Beckman SW41 rotor at 35000r.p.m. for 3h at 4 C),
each gradient was fractionated into 1-ml aliquots using a
gradient fractionator (Brandel) and monitored by optical
density measurement (A254). For RT-qPCR, each fraction
was diluted with an equal volume of water and RNA was
isolated using Trizol (Invitrogen, Carlsbad, CA, USA).
For western blotting, 15ml of each fraction was denatured
in 15mlo f1  Laemmli buﬀer.
RNA isolation and PCR analysis
RNA was extracted from whole-cell lysates, IP materials
or sucrose gradient fractions, DNAse-treated and con-
verted into cDNA using the AMV reverse-transcription
system (Promega, Madison, WI, USA) in the presence of
random hexamers (Invitrogen). The cDNA was used for
conventional PCR or RT-qPCR with gene-speciﬁc
primers as shown in Supplementary Data. An MYIQ
RT-PCR detection system and SYBR green PCR mix
(Bio-Rad, Richmond, CA, USA) were used to carry out
the RT-PCR. The relative quantization of targeted genes
was determined by the comparative Ct (threshold)
method using actin as an internal control (7). All data
were analyzed from three independent experiments and
statistical signiﬁcance was validated by Student’s t-test.
Aﬃnity puriﬁcation of GST- or His-EBP1 fusion proteins
In vitro expression and puriﬁcation of recombinant
His-EBP1 (a gift from Dr E. Spicer, Medical University
of South Carolina) or GST-EBP1 fusion proteins were
prepared as described (24).
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For in vitro synthesis of biotinylated AR and GAPDH
30UTR transcripts, cDNA from LNCaP cells was used
as a template for PCRs. The T7 RNA polymerase
promoter sequence (CCAAGCTTCTAATACGACTCA
CTATAGGGAGA) was added to the 50-end of all frag-
ments. Primers used for the ampliﬁcation of sequences of
partial GAPDH 30UTR, AR 30UTR-A, B, C or D are
shown in Supplementary Data. Biotinylated transcripts
of AR CAG9, 20, 44 were transcribed using a
MaxiScript T7 kit (Ambion) according to the manufac-
turer’s instructions with linearized pcDNA-AR-Q9, Q20,
Q44 (25) as templates. Bcl2 transcripts were transcribed
using the pCR4-ARE constructs containing the 137-nt
ARE
bcl-2 motif (921–1057-nt of bcl-2 cDNA) (18). Biotin
pull-down assays were carried out as described previously
(12). Brieﬂy, whole-cell lysates (40mg for each sample)
or 150ng of His- or GST-EBP1 fusion proteins were
incubated with 1mg of biotinylated transcripts for 1h
at room temperature. Complexes were isolated with
paramagnetic streptavidin particles (Promega) and
bound proteins were assayed by western blotting using
antibodies recognizing EBP1 or GST (Santa Cruz).
Transient transfection and luciferase assays
The pGL3-ARUC plasmid was constructed as previously
described (26) by fusing the UC-rich region of the 30UTR
of AR mRNA in frame to the 30-end of the Fireﬂy-
luciferase (Luc) coding sequence. A16 and C13 cells
were grown to 70% conﬂuence prior to transfection in
triplicate wells with 1mg of either pGL3-ARUC or
pGL3-Luc control vector (PGL3-con) using FuGene 6
(Roche). Cells were cotransfected with 5ng of TK-
Renilla reporter as a transfection control. Luciferase
activity was determined using the Promega Dual luciferase
activity kit according to the manufacturer’s instructions.
Data from three independent experiments were processed
as previously described (9,27).
Western blotting analysis
Western blot analysis was done as described previously
(8). The EBP1 antibody was from Upstate, the
monoclonal anti-b-actin and anti-GADPH antibodies
were from Sigma, and the polyclonal antibodies against
eIF2a and phospho-eIF2a (Ser51) were from Cell
Signaling. The monoclonal antibody against Rrp46 was
from Novus Biologicals (Littleton, CO, USA). The
monoclonal antibody against AR was from Santa Cruz.
Statistical analysis
qRT-PCR and luciferase assays were performed in tripli-
cate and repeated at least three times and western blotting
assays were repeated three times. All data presented
represent one individual experiment. Where appropri-
ate, means comparison were made using a two-tailed
Student’s t-test with a=0.05.
RESULTS
EBP1 promotes AR mRNA decay
Previous work from our laboratory showed that ectopic
expression of EBP1 decreases the levels of AR mRNA and
protein (7). However, AR protein stability was not
changed by EBP1 overexpression (Supplementary Figure
S1). To test if EBP1 is involved in post-transcriptional
regulation of AR, we ﬁrst measured AR mRNA half-life
in LNCaP cells overexpressing EBP1. As shown in
Figure 1A(i), AR mRNA stability was signiﬁcantly
(P<0.05) reduced in LNCaP cells stably transfected
with EBP1 cDNA (t1/2=2.98h) compared with vector
control (t1/2=5.19h). The results for AR mRNA half
life in LNCaP cells are consistent with previously pub-
lished data (28). Since EBP1 negatively regulates the
HRG-triggered signaling and the AR axis (7–9,27),
we examined the eﬀect of HRG on EBP1-induced accel-
eration of AR mRNA decay. As shown in Figure 1A(i),
HRG treatment led to a small but signiﬁcant (P<0.05)
decrease in the stability of AR mRNA in LNCaP vector
controls (t1/2=4.1h with HRG treatment versus 5.19h
without treatment) in keeping with recently published
data (29). However, HRG treatment had an even greater
eﬀect on AR mRNA decay rates in LNCaP cells stably
transfected with EBP1 (t1/2=1.29h with HRG treatment
versus t1/2=2.98h no treatment, P<0.05). The half-life
of a control GAPDH mRNA was not signiﬁcantly
aﬀected (P>0.05) by either EBP1 overexpression or
HRG treatment [Figure 1A(ii)]. Moreover, ectopic expres-
sion of EBP1 led to a signiﬁcant decrease in the steady-
state levels of AR mRNA and protein [Figure 1B(i and ii)]
in the LNCaP unrelated 22Rv1 line, indicating that EBP1
inhibition of AR is not cell type-speciﬁc.
We studied the role of EBP1 in regulating AR mRNA
stability using LNCaP EBP1-silenced C13 cells and the
control A16 cells that were previously described (8).
Brieﬂy, to derive the A16 and C13 cell lines, LNCaP
cells were transduced with lentiviral particles correspond-
ing to diﬀerent shRNA constructs targeted to the PA2G4
(EBP1) gene. Five individual shRNA lentiviral particle
constructs were tested. Only one construct (13C), corre-
sponding to NT 302–322 of PA2G4 (Genbank
NM_006191.1), inhibited EBP1 expression. Another con-
struct, 16A, did not inhibit EBP1 expression and served as
a control.
A16 cells express a comparable level of EBP1 as LNCaP
cells stably transfected with pcDNA vector (data not
shown). Abrogation of EBP1 expression signiﬁcantly
elevated the basal steady-state level of AR mRNA
[Figure 1C(i)]. HRG treatment resulted in a further signif-
icant (P<0.05) decrease in AR mRNA in A16, but not in
C13 cells. Under regular culture conditions, EBP1
silencing (C13) led to an increase in basal steady-state
levels of endogenous AR protein [Figure 1C(ii)], consis-
tent with the observation in EBP1-knock-out animals (10).
HRG treatment also reduced the AR protein level in C13
cells. However, this level was still signiﬁcantly higher than
that in A16 cells [Figure 1C(ii)]. To determine if
the increased expression of AR mRNA in EBP1 ablated
cells was due to changes in mRNA stability, we measured
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Figure 1. EBP1 promotes AR mRNA decay. (A) The stability of AR and GAPDH mRNA was analyzed in LNCaP cells transfected with vector
control (pcDNA) or with EBP1. Total cellular RNA was isolated at the indicated times after treatment with Act D. The remaining levels of AR and
3622 Nucleic Acids Research, 2010,Vol.38, No. 11AR half-lives. The half-life of AR mRNA was 4.96h in
the control A16 cells, but 9.8h in C13 cells [(P<0.0001),
Figure 1C(iii)], suggesting that ablation of EBP1 stabilized
AR mRNA. HRG treatment decreased the AR mRNA
half-life from 4.96h to 2.98h (P<0.0001) (in A16 cells,
similar to what was observed in parental LNCaP cells
[Figure 1C(iv)]. In contrast, HRG did not signiﬁcantly
change AR mRNA half-life in C13 cells (t1/2=9.8h
without treatment versus t1/2=9.2h with HRG)
(P>0.05). The half-life of a control house-keeping tran-
script (GAPDH mRNA) was not markedly diﬀerent in
these cell lines in the presence or absence of HRG
(P>0.05) [Figure 1C(iii)].
EBP1 interacts with AR mRNA
EBP1 is an RNA-binding protein with broadly similar
aﬃnity for single- and double-stranded RNA (20). To
address if EBP1 functions as an AR mRNA binding
protein, we determined if AR mRNA was present in
EBP1 immunoprecipitates. We found AR mRNA in
EBP1 immunoprecipitates from the A16 cell line
(Figure 2A), but not from the EBP1 knockout C13 cell
line (Figure 2A). A known EBP1-interacting transcript,
Bcl-2 mRNA (18) was also detected in EBP1 immunopre-
cipitates from A16 but not C13 cells (Figure 2A). Neither
AR nor Bcl-2 mRNA was precipitated by control IgG
(Figure 2A). Actin mRNA is a highly abundant mRNA
that is present as a low-level contaminant in the IP mate-
rials, and thus served to monitor the equal input of lysate
(30) (Figure 2A). The assay was also validated by the
positive association between HuR and its target AR
mRNA (26) in A16 but not C13 cells (Figure 2B). To
determine if the EBP1-AR mRNA interaction was
direct, we measured the ability of recombinant EBP1 to
bind AR mRNA. GST-tagged recombinant EBP1 was
incubated with A16 and C13 lysates, both sources of AR
mRNA. In vitro GST-pull-down assays demonstrated that
AR mRNA from both A16 and C13 lysates bound to
recombinant EBP1 (Figure 2C).
A UC-rich sequence has been identiﬁed in the proximal
AR 30 UTR that is implicated in AR mRNA stability (26).
As EBP1 aﬀected AR mRNA decay, we examined the
ability of EBP1 to interact with this region. Several
biotinylated transcripts spanning this region were
synthesized (Figure 3A) and the interaction between the
biotinylated transcripts and recombinant His-EBP1 fusion
proteins was assessed by biotin pull-down assays followed
by western blot analysis. As shown in Figure 3B, equal
amounts of puriﬁed full-length EBP1 protein interacted
speciﬁcally with a 397-nt region of the 30UTR containing
the AR UC-rich element (fragment A). A shorter 104-nt
fragment (fragment C) containing the UC-rich fragment
also bound EBP1. The fact that binding was decreased
between EBP1 and the UC-rich region alone (fragment
C) compared to the full-length region suggests that the
sequences spanning both sides of the UC-rich region
GAPDH mRNAs were measured by RT-qPCR analysis. Data from Act D assays were processed by Prism 3.03 software to calculate the time
required for each mRNA to reach one-half of its initial abundance and P-value. Values are means±SD of triplicates. Results are representative
among three independent experiments. (B) AR expression in 22Rv1 cells: (i) Total RNA was extracted from vector control and EBP1 transfected cells
to detect the steady-state levels of AR and house-keeping actin mRNAs by RT-qPCR. Graph (mean±SEM) is shown from three independent
experiments. (ii) The steady-state level of AR protein was measured by immunoblotting with antibodies to AR and actin. Flag antibody veriﬁed the
stable expression of Flag-tagged EBP1. (C) (i) A16 and C13 cells were either left untreated or treated with HRG (20ng/ml) for 24h. Total RNA
(triplicate wells) was then extracted to detect the steady-state levels of AR and b-actin mRNAs by RT-qPCR. (ii) Upper panel: The steady-state levels
of AR and actin in control A16 and C13 EBP1-silenced cells were measured by western blot analysis as described in the ‘Materials and Methods’
section. Lower panel: A16 and C13 cells were serum starved and then treated with HRG (20ng/ml) for 12h. (iii and iv) The stability of AR and
GAPDH mRNA in A16 control and C13 EBP1-silenced cells was analyzed. Total cellular RNA was isolated at indicated times after treatment with
Act D. The remaining levels of AR and GAPDH mRNAs were measured by RT-qPCR analysis. Data from Act D assays were processed by Prism
3.03 software to calculate the time required for each mRNA to reach one-half of its initial abundance and P-value. Values are means±SD of
triplicates. Results represent one of three independent experiments.
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Figure 2. Endogenous EBP1 interacts with AR mRNA. (A and B)T o
assess the association of endogenous EBP1 and HuR with endogenous
AR mRNA, lysates of A16 control lysates or C13 EBP1-silenced cells
were immunoprecipitated with antibodies recognizing EBP1 or with
control IgG (A), or with an antibody recognizing HuR and control
IgG (B). RNA was extracted and used as a template for cDNA syn-
thesis followed by PCR ampliﬁcation using primers speciﬁc for AR,
Bcl-2 or actin. PCR products were visualized after electrophoresis in
ethidium bromide-stained agarose gels. Actin mRNA is a highly
abundant mRNA that is present as a low-level contaminant in the IP
materials, and thus serves to monitor the equal input of lysate. (C) A16
and C13 lysates were incubated with GST or GST-EBP1 as described in
the ‘Materials and Methods’ section. GST complexes were isolated with
glutathione–agarose beads and RNA present in the pull-down was
detected by RT-PCR as described in (A and B).
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and D that did not contain the UC-rich region were
unable to bind EBP1 (Figure 3B). Recombinant EBP1
did not interact with the GAPDH 30UTR (Figure 3B).
We further examined the ability of endogenous EBP1 to
bind the UC-rich sequence. A16 and C13 lysates were
incubated with fragment C containing the UC-rich
region. EBP1 was detected by immunoblotting. Lysates
of A16 but not C13 cells bound the UC-rich sequence
(Figure 3C).
RNA-binding proteins have also been postulated to
inﬂuence AR gene expression by interacting with the
CAG polyglutamine repeat, which is predicted to form a
stable stem-loop structure (21) at the 50-end of the coding
sequence in the AR mRNA. Considerable interest has
been focused on this CAG trinucleotide repeat sequence
as repeats of diﬀering length are associated with diﬀerent
risks for prostate cancer (31,32). Short CAG repeats (<21)
are associated with higher risk of prostate cancer, while
longer repeats are associated with lower transcriptional
activity. An average repeat length of 20 is considered to
be associated with a normal phenotype (21). We therefore
examined the ability of EBP1 to interact with the CAG
repeat. CAG repeat probes were ﬁrst transcribed in vitro
with T7 RNA polymerase in the presence of linearized
pcDNA-AR-Q9, Q20 or Q44 constructs (25) and
biotin-11-CTP. The results of in vitro biotin pull-down
assays indicated that CAG9, 20 and 44 repeats associated
with recombinant His-tagged EBP1 (Figure 4A) (18). To
detect binding in vivo, CAG20 transcripts were incubated
with A16 and C13 cell lysates and associated proteins
detected by biotin pull-down assays. As the CAG20
repeat is most commonly found in normal prostate epithe-
lial tissue, it was used for further studies. The biotinylated
CAG20 transcript associated with endogenous EBP1
from A16 cell lysates (Figure 4B). As expected, EBP1
was not detected in biotin pull-down assays using
EBP1-silenced C13 cells. EBP1 derived from A16 lysates
was unable to bind the GAPDH 30UTR (Figure 4C), sug-
gesting the interaction of EBP1 with the AR 30UTR was
speciﬁc.
We next mapped the domain of EBP1 responsible for
the binding to CAG and UC-rich sequences. A schematic
of the constructs and the expression of the GST proteins
are presented in Figure 5A and B. We found that the
C-terminus of EBP1 (aa 322–394) bound both the CAG
and 30UTR of AR mRNA. Mutation of
354LKALL
358 to
LKAAA abolished the interaction of EBP1 with the
UC-rich sequence, but had no eﬀect on binding to the
CAG repeat (Figure 5C). It is of interest that stable
overexpression of the LKAAA mutant form of EBP1 in
LNCaP cells does not decrease expression of AR protein
(Figure 5D) and thus would be unlikely to aﬀect AR
mRNA stability. Previous data have indicated that
mutant and wild-type EBP1 are expressed at the same
level (9).
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UC-rich motif within the 30-UTR
Previous work has demonstrated that the UC-rich element
in the AR 30UTR to which EBP1 binds accelerates AR
mRNA decay (26). To determine if EBP1 aﬀects the
ability of the UC-rich region to accelerate AR mRNA
decay, we performed luciferase reporter assays in
EBP1-expressing and EBP1-silenced cells. The UC-rich
region in the 30UTR of AR mRNA was fused in-frame
to the 30-end of the ﬁreﬂy-luciferase coding sequence
(pGL3-ARUC) (26). A reporter plasmid lacking the
UC-rich region (pGL3-con) served as a control
(Figure 6A). As shown in Figure 6B, the presence of the
AR UC-rich sequence signiﬁcantly (P=0.0087) reduced
reporter activity in A16 cells, as previously demonstrated
in the parental LNCaP cell line (26). In contrast, the
activity of the chimeric pGL3-ARUC plasmid
signiﬁcantly (P=0.0023) increased after silencing EBP1
in C13 cells. Deletion of EBP1 thus appeared to abolish
the inhibitory eﬀects of the UC 30 UTR.
Considering the fact that luciferase activity measures
the eﬀect of EBP1 on both translation and mRNA stabil-
ity, we performed a parallel set of transfections to deter-
mine the Luc mRNA decay rate. Degradation of the
pGL3-ARUC transcript (t1/2=3.45h) was signiﬁcantly
(P<0.0001) accelerated compared with the control
pGl3-con (t1/2=5.18h) in A16 cells, indicating that
inserting the UC-rich sequence led to a signiﬁcant
destabilization of the reporter transcript. Moreover, the
half-life of pGL3-ARUC was signiﬁcantly (P<0.05) pro-
longed from 3.45h in A16 to 4.21h in the EBP1-silenced
C13 cell line [Figure 6C(i)]. Thus, the reduced reporter
activity resulted from the accelerated decay of the
reporter mRNA. The half life of GAPDH mRNA was
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whether the luciferase control of the Luc-UC construct
was transfected [Figure 6C(ii)].
EBP1 aﬀects AR mRNA association with polysomes
We have previously demonstrated that ectopic expression
of EBP1 results in a 5-fold decrease in AR protein levels.
However, AR mRNA levels were decreased only 2-fold
(7). In addition, AR protein stability was not changed
by EBP1 overexpression (Supplementary Figure S1).
As EBP1 binds to CAG regions in AR mRNA postulated
to play a role in translational control (21,26), we
hypothesized that EBP1 may modulate not only AR sta-
bility, but also its translation. To test this possibility, we
investigated the distribution of AR mRNA associated
with polysomes in EBP1 depleted LNCaP cells.
Equal amounts of cytoplasmic extracts of logarithm-
ically growing A16 and C13 cells were fractionated by
sucrose gradient centrifugation in the absence of EDTA
to preserve polysome integrity. Reading of absorbance
at A254 indicates the distribution of monosomes and
polysomes. The pattern is comparable in A16
(Figure 7A, left top panel) and C13 cells (Figure 7A,
right top panel), indicating that ablation of EBP1
expression did not trigger signiﬁcant changes in general
translation. Western blot analysis of the diﬀerent frac-
tions of the gradient identiﬁed the association of EBP1
with 40s, 60s and 80s ribosomes. EBP1 co-puriﬁed with
eIF2a, a component of the translation initiation com-
plex, as has been previously reported in HeLa cells
(17,24,33,34). eIF2a was not phosphorylated in either
A16 or C13 cells, consistent with the active translation
of AR that was observed. We also observed that EBP1
and Rrp46 cosedimented. Rrp46p is one of six RNase-PH
domain subunits in the exosome, an evolutionarily highly
conserved 30–50 exoribonuclease complex existing in both
the nucleus and the cytoplasm to degrade target mRNA
(35). Rrp46 has been previously shown to interact with
EBP1 in a yeast-two hybrid assay (36).
The relative abundance of AR mRNA in each
polysome fraction was next used to measure the degree
of engagement of the AR mRNA with the translational
apparatus. The percentage of AR mRNA shifted
towards a more translationally active polysome pool in
EBP1 knockout C13 as cells compared with control
A16 cells (Figure 7A, bottom left panel). The association
of a control house-keeping transcript (Actin mRNA)
with polysomes was not diﬀerent in the A16 versus
C13 groups (Figure 7A, bottom right panel).
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translation.
To investigate if HRG is involved in regulating the
association of EBP1 with polysomes and/or the AR
translational proﬁle, A16 and C13 cell lines were treated
with HRG and processed as described above. HRG treat-
ment led to a reduction in general translation in both A16
and C13 cells (Figure 7B, upper panel). HRG treatment
did not change the distribution of actin, Rrp46 or eIF2a
protein in either cell line. However, HRG treatment
induced the phosphorylation of eIF2a in A16, but not
C13 EBP1 knock out cells (Figure 7A, middle panel).
This ﬁnding was of interest, as phosphorylated eIF2a is
inactive, leading to inhibition of translation initiation.
HRG elicited a dramatic shift in the distribution of AR
mRNA in A16 cells towards untranslated fractions.
In contrast, EBP1 silencing in C13 cells abrogated such
a shift, as the majority of AR mRNA was still being mod-
erately translated after HRG treatment (Figure 7B,
bottom left panel). Actin continued to be actively
translated in both A16 and C13 cells after HRG treatment
(Figure 7B, bottom right).
DISCUSSION
Our current study has identiﬁed EBP1 as a novel AR
mRNA-binding protein that promotes AR mRNA
decay. The EBP1-mediated decay depended on the
presence of a UC-rich region in the 30-UTR of AR
mRNA that was previously identiﬁed as a destabilizing
element for interaction with RNA-binding proteins (21).
The fact that EBP1 expression is decreased in prostate
cancer suggests that its control of AR mRNA decay
may play a role in prostate cancer progression.
Similarly, HuR destabilizes AR mRNA and its subcellular
localization is de-regulated in a subset of prostate carci-
nomas (37). However, the functional consequence of HuR
binding to AR mRNA remains to be deﬁned.
The fact that EBP1, HuR (a member of the ELAV/Hu
group) and PCBPs [poly(C) RNA-binding proteins] all
bind to this region of AR mRNA suggests that this
short UC-rich region is capable of docking with several
RNA-binding proteins at once. It will thus be interesting
to dissect the kinetics of these interactions and the func-
tional impact of these proteins on AR expression. Further,
the fact that HuR and PCBPs jointly interact with the
30-UTRs of AR, p21
WAF1 and renin mRNAs suggests a
common model of multiple RNA-binding protein interac-
tion with a single RNA sequence (21). However, whether
EBP1 can bind to the 30UTRs of these other genes has not
yet been determined. In addition, the association of
exosome protein Rrp46 with EBP1 in polysome gradients
suggests another mechanism for EBP1-mediated decay of
AR mRNA. The ability of EBP1 to bind to RNA in
concert with other proteins is in line with the crystal struc-
ture of EBP1 that demonstrates that the C-terminal helix
10 with the LXXLL motif close to the putative RNA-
binding platform may provide an adjustable interface for
the interaction of EBP1 with diﬀerent partners (19).
EBP1 was able to bind both the CAG and 30UTR
sequences of AR mRNA. Similarly, heterogeneous nuclear
ribonucleoprtotein K (hnRNP K) was demonstrated to
bind to several regions within the AR mRNA (38).
A simultaneous interaction of EBP1 with two structured
RNAs seems feasible. Of note, EBP1 that was mutated in
its LXXLL domain was able to bind the CAG repeat, but
not the AR 30UTR. The LKALL sequence adopts the
helical structure common to LXXLL motifs and was
hypothesized to be important in EBP1’s interactions
with binding partners (20). However, the basis for the dif-
ferential aﬃnity for the CAG and 30UTR motifs is not
known. Nevertheless, we have demonstrated that the
LXAAA mutant unable to bind the 30UTR mRNA lost
its ability to inhibit AR expression.
In keeping with a recent report (28), we found that
treatment of LNCaP cells with HRG decreased expression
of endogenous AR mRNA due to increased AR mRNA
degradation. However, speciﬁc RNA binding proteins
that might have contributed to these HRG-induced
changes in AR mRNA stability were not identiﬁed in
that study. Many other ErbB3 binding proteins with a
possible role in prostate cancer have been identiﬁed and
may play a role in HRG-induced changes in AR mRNA
stability (13). We found that the HRG-induced decrease in
AR mRNA stability was greatly enhanced when EBP1
was ectopically expressed. In addition, the HRG-induced
accelerated decay of AR mRNA was abrogated in the
absence of EBP1. These ﬁndings suggest that EBP1 may
be an important mediator of the HRG-induced decrease in
AR mRNA. However, the fact that HRG still slightly
diminished AR levels in the absence of EBP1 suggests
that other proteins are involved in the HRG-induced
AR regulation. EBP1 was initially isolated as an ErbB3-
binding protein and its phosphorylation and activity are
signiﬁcantly aﬀected by treatment with the ErbB3 ligand
HRG (26,39). EBP1 is phosphorylated on Thr261 after
HRG treatment by PAK1(40). Thus, it is possible that
PAK1 may be important in mediating HRG’s eﬀect on
AR mRNA decay. In keeping with this, AR down-
regulation in response to HRG was not aﬀected by
and 254-nm absorbance was recorded. Middle panel: Western blot analysis (WB) was used to measure the levels of EBP1, p-eIF2a, eIF2a, Rrp46 and
Actin in each fraction from A16 (left panel) and C13 (right panel) cells. Lower panel: The levels of AR and house-keeping Actin mRNAs in each
gradient fraction were measured by RT-qPCR and plotted as a percentage of the total AR (bottom left panel) or Actin mRNA levels (bottom right
panel) in that sample. The translational activity associated with each fraction is indicated as untranslated (NT, not translated), moderately translated
(LMW, low-molecular-weight polysomes) and actively translated (HMW, high-molecular-weight polysomes) as previously described (29). Data
represent one of three independent experiments showing similar results. (B) A16 and C13 cells were treated with HRG (20ng/ml) for 16h. Cell
lysates were processed as described in (A). Upper panel: Two-hundred and ﬁfty-four nanomolar absorbance proﬁles. Middle panel: Western blot
analysis (WB) of polysome fractions. Lower panel: The levels of AR and house-keeping Actin mRNAs in each gradient fraction were measured by
RT-qPCR and plotted as a percentage of the total AR (bottom left panel) or Actin mRNA levels (bottom right panel) in that sample. Data represent
one of three independent experiments showing similar results.
3628 Nucleic Acids Research, 2010,Vol.38, No. 11ERK or PI3-kinase inhibition (28). Thus, EBP1 is the ﬁrst
endogenous protein demonstrated to promote AR mRNA
decay in an HRG-inducible manner, providing novel
insights into cross-talk between HRG-activated
pathways and AR signaling (1,41,42).
AR protein levels have also been shown to be regulated
by changes in AR mRNA translation. For example,
hnRNP K has been shown to regulate AR translation
(38). In our study, EBP1 also repressed AR translation.
A shift towards more translationally active ribosomes was
observed in polysome fractions in the absence of EBP1. In
contrast, loss of EBP1 had no eﬀect on the distribution of
Actin mRNA. Further, HRG treatment shifted AR
mRNA to translationally inactive ribosomes in the
presence, but not the absence, of EBP1. These ﬁndings,
taken with work of others indicating an involvement of
EBP1 in translation (17,20), suggest that EBP1 might
inhibit translation initiation of AR mRNA. Indeed,
our analysis of sucrose density gradients showed that
EBP1 cosediments with 40S, 60S and 80S ribosomes, con-
sistent with previous reports that EBP1 is part of RNP
complexes (16,17,19). Moreover, EBP1 has been identiﬁed
as an internal ribosomal entry site (IRES)-trans-acting
factor (43).
At present, we do not know which region of the AR
message is responsible for the eﬀects of EBP1 on transla-
tion. Mukhopadhyay et al. (38) demonstrated that
hnRNP-K uses regions within the AR coding region
to regulate translation. We suggest that the CAG
trinucleotide repeat at the 50-end of AR exon 1, which is
predicted to form a stable stem-loop structure, might
function similar to an IRES element, which usually
consists of a highly structured RNA regions located at
the 50UTR of viral or cellular mRNAs (44). A possible
link between EBP1 and both mature ribosomal subunits
and CAG-formed stem-loop of AR mRNA might consti-
tute a basis for cell-speciﬁc translational control of AR
mRNA by aﬀecting their assembly into a stable RNP
complex and/or eﬃcient elongation. Such repression is
well characterized in ferritin mRNA containing a
stem-loop structure (iron-responsive element) in a cap-
proximal 50UTR. Binding of the iron regulatory protein
to the iron-responsive element prevents recruitment by
eIF4F of the 43S ribosomal complex to the cap-proximal
region of the 50UTR before scanning to the initiation
cordon (45).
Our previous work indicated that EBP1 diminishes
transcription of AR and several of its target genes (7,8).
These ﬁndings, in combination with the current work,
indicate that EBP1 may aﬀect AR at both the trans-
criptional and post-transcriptional levels. The integrated
action of EBP1 at through these mechanisms provides an
eﬀective program to attenuate AR signaling. Such biology
has been reported for several proteins (46). PCBPs,
members of the hnRNP K homology domain family of
RNA-binding proteins, modulate RNA stability and
also facilitate or inhibit translation. HnRNP K can simi-
larly function to both regulate AR translation (28)
and transcription (47). EBP1 is a member of the
Proliferation-associated 2G4 gene family which is
comprised of 30 identiﬁed homologs that are highly
conserved in organisms ranging from Danio rerio to Pan
troglodytes (48). These proteins are involved in the regu-
lation of cell growth, diﬀerentiation and apoptosis (13,14)
by a variety of mechanisms. As the human member of the
family, EBP1 has a profound impact on physiologic and
pathologic process (13,14), further evidenced by our
current study.
Our ﬁndings also provide a new rationale for clinical
treatment of prostate cancer. Reduction of EBP1 in
prostate cancer, as recently documented (7,8), might ﬁrst
impair the co-repressor machinery for transcription;
second, EBP1 reduction could result in changes in
post-transcriptional regulation of AR contributing to
aberrant expression of AR and a subsequent impact on
castration-resistant metastasis. An inverse relationship
between EBP1 and AR mRNA levels in metastatic and
organ-conﬁned proste tumors has recently been reported
(49,50) (Supplementary Figure S2). The development of
EBP1-based modiﬁers of AR mRNA in target tissues is
thus envisaged as a potent therapeutic approach for the
treatment of prostate cancer.
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